Private Markets, Angel and Secondary Investing, Sacra

Sacra

Bringing transparency to private markets so investors, founders, and employees can build on conviction.

Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>Sacra estimates that Hone Health hit $113.5M in annual recurring revenue (ARR) in September 2025, up from $69.7M at the end of 2024.</li><li>The women&#39;s business launched in January 2025 and is already growing faster than the core men&#39;s testosterone business.</li><li>Hone Health closed a $33 million Series A in January 2025 led by Tribe Capital.</li></ul>

Sacra estimates that Hone Health hit $113.5M in annual recurring revenue (ARR) in September 2025, up from $69.7M at the end of 2024.The women&#39;s business launched in January 2025 and is already growing faster than the core men&#39;s testosterone business.Hone Health closed a $33 million Series A in January 2025 led by Tribe Capital.

Hone Health

Primer: Hone Health - 19 Oct 2025